Avastin fails to hit colon cancer target
Wednesday, April 22, 2009 - 22:35
in Health & Medicine
SAN FRANCISCO, April 22 (UPI) -- The drug Avastin fell short in a clinical trial of its goal to reduce the recurrence of early-stage colon cancer, U.S. drug maker Genentech says.